PCSK9 rs11206510: What Your Genotype Means
The rs11206510 variant is a single nucleotide polymorphism located within the PCSK9 gene, which plays a critical role in cholesterol metabolism. Research has identified this variant as being associated with variations in lipid profiles and cardiovascular health outcomes.
What each genotype means
Typical cholesterol regulation
This is the most common genotype for this variant in many populations. It does not carry the specific genetic association linked to lower LDL cholesterol levels observed with the T allele. Please consult your physician for routine cardiovascular health screenings and cholesterol management.
Carried by the majority of individuals globally, as the T allele is the less common variant.
Reduced LDL cholesterol association
This genotype is associated with lower levels of LDL cholesterol compared to the CC genotype. Research suggests this variant may offer a protective effect against cardiovascular risk, though it has also been studied for potential associations with minor changes in fasting glucose and body weight. Discuss your lipid profile and cardiovascular health with your clinician.
The T allele has a minor allele frequency of approximately 17% in many studied populations, making this heterozygous genotype relatively common.
Enhanced LDL cholesterol reduction
Individuals with this genotype typically show the strongest association with lower circulating LDL cholesterol levels among the three possible genotypes. While this is considered a protective trait for heart health, it is important to maintain regular medical check-ups to monitor your overall metabolic health. Always discuss your cholesterol levels and any health concerns with your healthcare provider.
This is the least common genotype, occurring at a frequency consistent with the 17% minor allele frequency of the T allele.
Understanding the rs11206510 Variant
The rs11206510 variant is a specific genetic marker located on chromosome 1 within the PCSK9 gene region. In genetics, a single nucleotide polymorphism (SNP) like rs11206510 represents a variation at a single position in the DNA sequence. While many SNPs have no observable effect on health, researchers study those in the PCSK9 gene closely because of the gene's well-established role in regulating cholesterol levels. This particular variant is often analyzed in the context of genome-wide association studies (GWAS), which look for statistical links between specific genetic markers and physical traits or disease risks across large groups of people. Because rs11206510 is located in a non-coding region of the gene, its exact biological mechanism is still a subject of ongoing scientific investigation, distinguishing it from rare, high-impact mutations that directly alter the protein's structure.
The Role of the PCSK9 Gene
The PCSK9 gene provides instructions for making a protein called proprotein convertase subtilisin/kexin type 9. This protein is primarily produced in the liver and plays a vital role in cholesterol homeostasis. Under normal conditions, the PCSK9 protein binds to low-density lipoprotein (LDL) receptors on the surface of liver cells. Once bound, it promotes the degradation of these receptors, preventing them from clearing LDL cholesterol—often called 'bad' cholesterol—from the bloodstream. By reducing the number of available receptors, PCSK9 effectively increases the amount of LDL cholesterol circulating in the blood. Because of this function, the PCSK9 gene has become a major target for therapeutic development. Medications known as PCSK9 inhibitors work by blocking this protein, thereby allowing more LDL receptors to remain active and clear cholesterol from the blood more efficiently.
Research Associations and Evidence
Scientific research has consistently linked variations in the PCSK9 gene to differences in cardiovascular health. While some rare mutations in PCSK9 are known to cause familial hypercholesterolemia—a condition characterized by very high cholesterol—other common variants are studied for their potential to influence cholesterol levels in the general population. The rs11206510 variant has been identified in large-scale meta-analyses as having a statistical association with lipid metabolism and ischemic heart disease risk. It is important to note that the evidence for this specific SNP is based on population-level statistical associations rather than direct causation in every individual. The strength of these associations can vary depending on the ancestry of the study participants and other environmental factors, such as diet, lifestyle, and the use of cholesterol-lowering medications like statins.
Population Frequency
Genetic variants are distributed differently across global populations, and rs11206510 is no exception. Current data from large genomic databases indicate that this variant is present in approximately 2-3% of the global population, though this frequency can fluctuate significantly between different ancestral groups. Understanding these frequency differences is a key component of modern genomics, as it helps researchers determine whether a genetic association is universal or specific to certain populations. Because the variant is relatively common, it is frequently included in genetic risk scores that aim to provide a more comprehensive picture of an individual's genetic predisposition to lipid-related traits. However, frequency alone does not determine the clinical significance of the variant for any single person.
Interpreting Your Genetic Information
If you have received information about your rs11206510 genotype, it is essential to view it within the context of your overall health. Genetic markers are only one piece of a complex puzzle that includes your medical history, lifestyle, and environment. Having a specific genotype does not guarantee a particular health outcome, nor does it replace the need for standard clinical screenings. If you are concerned about your cholesterol levels or cardiovascular risk, the most important step is to consult with a healthcare professional. They can interpret your results alongside standard blood tests and clinical assessments. Never make changes to your medications or health regimen based solely on genetic reports; always discuss your findings and any potential implications for your care with your doctor or a qualified pharmacist.
How common is this variant?
The rs11206510 variant is found in approximately 2-3% of the global population, with frequencies varying across different ancestral groups.
Frequently asked questions
Does having the rs11206510 variant mean I have high cholesterol?
No, a single genetic variant does not determine your cholesterol levels. Cholesterol is influenced by a combination of genetics, diet, physical activity, and other health factors.
Can I use this information to choose a diet?
Genetic information is not a substitute for personalized medical advice. You should discuss your overall health and dietary needs with a registered dietitian or your primary care physician.
Is rs11206510 the same as the mutations that cause familial hypercholesterolemia?
No, rs11206510 is a common variant, whereas the mutations that cause familial hypercholesterolemia are typically rare and have a much more significant impact on cholesterol levels.
Should I get tested for this variant?
Routine testing for this specific SNP is not standard clinical practice. If you have concerns about your heart health, standard blood lipid panels are the primary tool used by doctors.
Sources & further reading
Educational information only, last refreshed 10/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11206510?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in PCSK9
The R46L loss-of-function missense variant leads to lower plasma LDL cholesterol levels and significantly reduced lifetime risk of coronary heart disease.
An upstream regulatory variant in PCSK9 influencing baseline low-density lipoprotein cholesterol levels and clinical response to statin therapy.
Also known as PCSK9 R46L, this loss-of-function variant is associated with significantly lower LDL cholesterol and decreased risk of coronary heart disease.